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Introduction
Trypanosoma cruzi is the causative agent of Chagas disease that affects 16-18 million 
people  in  Latin  America.  Further  100 million  people  are  at  risk  in  this  area  and ca.  50 
thousand  die  annually  from  this  disease.  The  infection  is  initiated  by  metacyclic 
trypomastigotes present in feces of triatomine bugs. Trypomastigotes invade vertebrate host 
cells and come in contact with the lysosomal compartment [Burleigh, 1995]. Chagas disease 
has also been recognized as an opportunistic disease in HIV-infected individuals [Coura and 
Castro,  2002]  in  addition  to  being  reported  throughout  the  world  due  to  international 
immigration [Días, 2007].
Current  treatments  rely  on  two  old  and  non-specific  chemotherapeutic  agents, 
Nifurtimox  and  Benznidazole.  Despite  the  major  advances  that  have  been  made  in  the 
identification of specific targets that afford selectivity, the drugs used today have serious side 
effects. Furthermore, differences in drug susceptibility among different T. cruzi isolates have 
led to varied parasitological cure rates depending on the geographical region. Due to these 
inadequacies, an intense research program has been directed to find alternative drugs for the 
treatment of chagasic patients [Urbina, 2010]. 
A number of drugs were reported to be effective against T. cruzi in vitro or in animal 
models, but no drug proved to be completely satisfactory for clinical use. Similarly, there are 
no adequate chemoprophylactic drugs to be used to eliminate the parasite from the blood of 
serologically  positive  donors  in  order  to  prevent  transfusion-associated  Chagas  disease. 
Therefore,  new compounds  showing higher  potency and selectivity  in  both the acute and 
chronic stages of Chagas disease and/or perhaps, even more importantly, better tolerability are 
urgently needed [Guedes, 2011; Muñoz, 2011].
In our grant proposal  we suggested to test glycosyl disulfide derivatives  against T. 
cruzi.  Novel  glycomimetics  containing  disulfide  interglycosidic  linkages  were  first 
synthesized in our laboratory [Szilágyi, 2001]. We have developed further synthetic methods 
for various structures [Murthy,  2009, Stellenboom, 2010, Illyés,  2011], studied the lectin-
binding  properties  of  some  derivatives  [Murthy,  2009]  and  determined  conformational 
preferences [Fehér, 2011]. We have reasoned that this type of glycosidic linkage, featuring a 
three-bond distance between the anomeric carbon and the aglycon as opposed to the two-bond 
natural glycosidic bonding [Szilágyi & Varela 2006], provides a larger conformational space 
for  these  compounds  [André,  2006;  Fehér,  2011].  Furthermore,  differences  in  the 
stereoelectronic properties of the bridging S-atoms may promote interactions with proteins 
which  are  different  from  those  with  O-glycosides.  In  fact,  it  was  recently  shown  that 
appropriately positioned symmetric diglycosyl disulfides are binding to various lectins [Pei, 
2005] Subsequently, our own studies disclosed specific lectin-binding affinities of multivalent 
aromatic  glycosyl-disulfide  derivatives  [Murthy,  2009].  Moreover,  increased  physiological 
relevance of these novel carbohydrate structures have been clearly demonstrated in assays 
with native tumor cells such as human B- or T-lymphoblastoid- and adenocarcinoma cell lines 
[André, 2006]. A further significant evidence regarding biological activities of disulfide-type 
sugars was the observation that hemagglutination by Streptococcus suis was strongly inhibited 
by aromatic sugar derivatives [Hansen, 1997] similar to those in the 2nd group of compounds 
(see  below)  we  proposed  to  test.  The  value  of  such  disulfide  sugar  derivatives  in 
physiologically relevant interactions is, therefore, clearly documented. Based on the foregoing 




The chemical structures of the compounds tested in this study are shown in Chart 1. Aromatic 
glycosyl disulfides 2b – 5b have been previously described [Murthy, 2009]. 1a-3a, 5a and 6a 
were prepared using similar procedures with the difference that the starting product 1-thio-
2,3,4,6-tetra-O-acetyl-α-D-mannopyranose was replaced by 1-thio-2,3,4,6-tetra-O-acetyl-β-D-
galactopyranose in these reactions.  7 and  8 were synthesized as published [Szilágyi,  2001, 
Bell & Horton, 1969, resp.].
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Chart 1. Compounds used for the antitrypanosoma tests
6a showed moderate trypanocidal activity (Table 1) but, in addition, it  is one of the most 
potent  inhibitors  of  β-galactosidase  (EC 3.2.1.23)  [De Bruyne,  1977] and a  radio  labeled 
derivative has also been used for imaging of LacZ gene expression. [Choi, 2003]. Therefore 
determination of its stereo structure is of multiple interest. We have therefore determined the 
structure of 6a by X-ray crystallography [Brito, 2011] 
Trypanocidal activities against tissue culture derivated trypomastigotes
T. cruzi (Y strain) trypomastigotes cell culture-derived were used in this study. HeLa cells 
were infected with trypomastigotes as previously described [González, 1996].  Experiments 
were carried out according to [González, 1991] with slight modifications. The trypanocidal 
activity  was  measured  as  IC50 using  a  resazurin  method  as  previously  described  [Rolon, 
2006].  All assays were carried out in triplicate using benznidazole (35-173 µM) as positive 
control. 
Trypanocidal activity against intracellular amastigotes
100 µl of a suspension containing 4 x 104 HeLa cells/ml were seeded on 96-well microplates 
and incubated for 18 h under a 5% CO2 atmosphere in order to obtain cell adherence. Next, 
the cells were washed and infected with cell culture derived trypomastigotes (Y strain) at a 
ratio of 5 parasites per cell, for 3 h.  Two days later, the infected culture was treated with each 
compound (25 µM) for 24 h and the activities against intracellular growth were determined by 
counting the number of trypomastigotes released after 5 days of intracellular development. 
Cytotoxic activity against mammalians cells
One hundred µl of a suspension containing 4 x 104/ml of HeLa cells, were added to 96-well 
microplates and the cells were left to adhere and grow for 24 h. Cells were washed with RPMI 
and incubated with different concentrations  of each compound for 24 h. Cytotoxicity was 
evaluated using a resazurin test. 
Results
The direct  effect  of  the glycosyl  disulfides  on tissue culture  derived trypomastigotes  was 
evaluated after 18 h of treatment at 37°C. The most active compounds was 3a with IC50 of 8.7 
±1.21 µM.  Other promising compounds were 2a, 2b and 5a that displayed IC50 values of 14.8 
±1.2, 14.2 ±1.2 and 14.5 ± 1.18 µM, respectively (Table 1). In the same way, the cytotoxic 
effect  of  active  and  inactive  compounds  were  evaluated  after  18  h  of  incubation  with 
confluent HeLa cells cultures.  3a, the most promising trypanocidal derivative proved to be 
cytotoxic only at an elevated concentration of 251.3 ±1.44  µM. Cytotoxic concentrations for 
2a, 3b  and 5b with low IC50 against  T.cruzi were similar or even higher  (Table 1). Finally 
the effects of the glycosyl disulfides on T. cruzi  infected HeLa cell cultures were evaluated 
after 18 h of treatment at 37°C (Figure 1). We observed that compound 3a strongly inhibited 
the intracellular development of T.cruzi amastigotes as well, as evidenced by a low release of 
trypomastigotes to the supernatant medium. Other compounds like 1a, 2b, 3b, 4b and 8 also 
displayed strong inhibition of parasite release suggesting an effect against the intracellular 
development  of  T.cruzi amastigotes.  None  of  the  compounds  were  cytotoxic  at  the 
concentrations assayed (Table 1).
 
Table 1.  Trypanocidal activities and cytotoxic concentrations
Compounds Trypanocidal activity
      IC50 (µM) 
    Cytotoxicity
     CC50  (µM)
1a 52,2 ±   1.23 >2000
2a 14,8 ±   1.2 247,5± 1.42
2b 14,2 ±   1.2 >2000
3a 8,7 ±   1.21 251,3± 1,44
3b 42,8 ±   1.34 500,8± 1.47
4b 98,4 ±   1.24 >2000
5a 14,5 ±   1.18 >2000
5b 233,3 ±   1.44 >2000
6a 238,2 ±   1.38 >2000
7 241,4±    1.42 >2000
8 111,8 ±  1.31 256± 1.38
Beznidazol 99,7   ±  1,5 ND
Fig.1 Infected HeLa cell cultures were incubated during 18 h with the compounds listed on 
the  x-axis.  The  activity  against  intracellular  development  was  evaluated  by  counting  the 
number of released trypomastigotes per mL.
Discussion 
Among possible  drug targets  in  trypanosome  organisms  the  enzyme  trypanothione 
reductase (TR) emerges as the most thoroughly studied system. This enzyme is essential in 
protecting  parasitic  protozoa  against  oxidative  stress  by  catalyzing  the  reduction  of 
trypanothione disulfide (TS2) to trypanothione (T(SH)2) [Krauth-Siegel, 2005]. This supports 
the strategy of  using  selective  inhibition  of  TR as  a  feasible  approach for  the  control  of 
trypanosomal  infections.  A  recent  high-throughput  screening  campaign  covering  100 000 
compounds [Holloway, 2009], mostly synthetic, identified five classes of chemical structures 
as potential candidates to be developed into antiparasitic drugs. Interestingly, just a few of the 
inhibitors  tested  contained  disulfide  bond  [El-Waer,  1991;  Gallwitz.,  1999].  Aromatic 
sulfides, on the other hand, were found to exert antitrypanosomal effects on several occasions 
[Stump, 2007; Girault, 2001]. 
In the present study we have reasoned that compounds incorporating disulfide bonds 
might be effective against  T.cruzi via interfering with the TR-mediated redox mechanism of 
the parasite. The compounds selected for the tests are characterized by the attachment of one 
or more monosaccharide sugars to an aromatic core (1a, 2a,b, 3a,b, 4b, 5a,b) or to another 
monosaccharide  (7 &  8)  by  disulfide  linkages.  Compound  6a,  of  similar  structure  but 
containing a simple sulfide bond, rather than disulfide, was added for comparison, see Chart 
1. Then, inspecting the results of our inhibition tests listed in Table 1 some conclusions can be 
drawn regarding possible structure-activity relationships. 
First,  sizeable  inhibitory  activities  were  observed  only  for  aromatic  disulfide 
derivatives (1a, 2a, 2b, 3a, 3b, 4b, 5a, with the exception of 5b). Second, the presence of both 
the aromatic ring and the disulfide linkage appear to be essential. This is clearly demonstrated 
by the much lower activity of derivatives 7 and 8 (no aromatic rings) on the one hand, and by 
the comparison of  1a to  6a, on the other. While the disulfide  1a is a moderate inhibitor of 
T.cruzi growth,  6a,  lacking just  one S-atom in comparison with  1a,  is ca. four times less 
active.  Another  remarkable  correlation  between  activity  and  structure  concerns  the 
substitution pattern on the aromatic ring: di- and trisubstituted derivatives (2a, 3a, 5a) are 
more  efficient  than  the  monosubstituted  1a.  Of  the  former  group  3a,  bearing  the  sugar 
disulfide substituents in para position, stands out with an IC50 of 8.7 ±1.21 µM, being ca. two 
times more active than  2a or  5a which have the same substituents in  meta positions. And 
finally, the striking difference of the inhibition efficiencies between 5a and 5b and, to a lesser 
extent,  between  3a and  3b bears evidence  for the importance  of the sugar  configurations 
attached to the aromatic ring: the β-galactosyl derivative  5a is ca sixteen times more active 
than  α-mannosyl-substituted  5b and,  similarly,  3a exceeds  3b five  times  in  inhibition 
efficiency against  T.cruzi epimastigotes. Molecule  3a clearly stands out as the most potent 
inhibitor of the tested panel with an efficiency comparable to or even exceeding that of the 
known drugs. In fact,  the antitrypanosoma activity of compound  3a was found more than 
eleven times higher than that of benznidazol (Table 1), a drug currently used in the treatment 
of Chagas disease. However in strong opposition to benznidazole,  3a was also capable of 
inhibiting the intracellular development of T.cruzi amastigotes. 
Although it may seem premature to speculate about possible molecular mechanism of 
inhibition from tests conducted on the whole parasites, some preliminary considerations may 
still be advanced at this stage. First, it seems reasonable to hypothesize that our disulfides may 
bind  to  the  TR  enzyme,  the  parasite-specific  disulfide  reductase.  The  binding  may  be 
facilitated / enhanced by the presence of the aromatic rings in our molecules which displayed 
inhibitory activities. Note that most of the known TR inhibitors contain aromatic moieties 
[Jacoby,  1996;  Krauth-Siegel,  2005;  Holloway,  2009].  The  significant  specificity  of  the 
inhibition potency on the chemical structure, as discussed above, is a further indication for the 
enzyme  binding.  TR  is,  however,  not  a  carbohydrate-binding  enzyme.  The  fact  that  the 
inhibition potency of 3a, a β-galactosyl derivative is much higher (Table 1) than that of the α-
mannosyl-bearing  3b may  indicate  that  another  Trypanosome-specific  enzyme  may  be 
implicated to interact with  3a. We hypothesize that this enzyme might be the  T.cruzi trans-
sialidase (TcTS). This transglycosidase is essential for the parasite to survive in the host’s 
bloodstream by transferring sialic acid from glycoconjugates on the surface of the host cells to 
terminal galactose units on the surface of the parasite as the latter is incapable to synthesize 
sialic acid [Damager, 2008]. The negatively charged sialic acid coat protects the parasite’s 
antigenic surface. Although validation of TcTS as a target for anti-T.cruzi chemotherapies is 
not without problems [Buscaglia, 2006] it is possible that 3a may interfere with this process 
via competition as an alternate acceptor for TcTS. Significantly, 3a was found to be the most 
efficient agent against intracellular amastigotes as well. In fact, its potency exceeded that of 
the benznidazol used as control by one order of magnitude (Fig. 1). Remarkably enough, 2a, a 
positional  isomer  of  3a,  on  the  other  hand,  was  very  poor  in  preventing  the  release  of 
trypomastigotes from the infected cells (Fig. 1). This may be a consequence of the strict steric 
requirements  for  the  putative  binding  of  these  inhibitors  at  the  binding  site  of  TcTS. 
Evidently, further studies with recombinant or purified enzymes would have to be conducted 
to elucidate these points. Finally, it is important to note that none of the compounds in this 
study were cytotoxic for the host cell (see Table 1). In fact, several compounds reported in the 
literature have been shown to kill T.cruzi. However, of outstanding interest is the observation 
that several of the compounds we tested were also able to inhibit intracellular proliferation or 
parasite differentiation when the number of parasites released by T.cruzi-infected Vero cells 
was evaluated. These observations show a remarkable effect of these compounds against the 
intracellular stage of T.cruzi, an activity that is missing in the currently available drugs like 
benznidazol and nifurtimox [Gutiérrez, 2011]. 
Work aimed at  optimizing the chemical  structures of glycosyl  disulfides and other 
closely  related  analogues  is  currently  being  pursued  in  our  laboratory  together  with 
experimental approaches focused to elucidate the inhibitory effect on TR and TcTS. 
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